US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
biotech · Attention Deficit Hyperactivity Disorder · Vascular Ehlers-Danlos Syndrome · AYTU
AYTU BIOPHARMA
AYTU BIOPHARMA, INC
AYTU BIOPHARMA drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Denver, USA HQ
2015 Founded
105 Employees
Public company Type
AYTU · NYSE Ticker
Company details
- Status
- Public
- HQ
- Denver, USA
- Founded
- 2015
- Employees
- 105
- Programs
- 3
- Drugs
- 5
- Patents
- 4
AYTU BIOPHARMA pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AYTU BIOPHARMA drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to AYTU BIOPHARMA in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to AYTU BIOPHARMA in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA A receptor alpha-1/beta-1/gamma-2.
- Target
- GABA A receptor alpha-1/beta-1/gamma-2
- Mechanism
- GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator